MIRA

Quote

Short

News

Articles

Message Board

MIRA Pharmaceuticals Inc. (NASDAQ : MIRA ) News

News Releases

MIRA News Releases

July 10, 2026 08:00:00 am

ACCESS Newswire

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain

July 06, 2026 09:00:00 am

ACCESS Newswire

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction

June 25, 2026 08:15:00 am

ACCESS Newswire

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC

June 17, 2026 08:00:00 am

ACCESS Newswire

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy

June 04, 2026 08:00:00 am

ACCESS Newswire

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1

May 27, 2026 08:00:00 am

ACCESS Newswire

MIRA Pharmaceuticals Secures Worldwide Rights for Ketamir-2, Expanding Global IP Portfolio Across 10 Major Markets Ahead of Phase 2a in CIPN

May 14, 2026 08:00:00 am

ACCESS Newswire

MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2

May 13, 2026 08:00:00 am

ACCESS Newswire

MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate

March 23, 2026 09:00:00 am

ACCESS Newswire

MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies

March 04, 2026 08:00:00 am

ACCESS Newswire

MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2

	Next 10

Subscribe to Our Newsletter

Download The Market Wire News App

Link Market Wire News to Your X Account